Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.67 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.67 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504432 | 1.00 | KCNH2 (0.67) | KCNH2OPRM1OPRL1CHRM4CHRM1 | |
| SCHEMBL6500952 | 0.86 | KCNH2 (0.66) | KCNH2OPRM1OPRL1CHRM4CHRM1 | |
| SCHEMBL6500956 | 0.86 | KCNH2 (0.66) | KCNH2OPRM1OPRL1CHRM4CHRM1 | |
| SCHEMBL6471689 | 0.81 | OPRM1 (1.00) | KCNH2OPRM1OPRL1CYP2D6 | |
| SCHEMBL6506055 | 0.79 | OPRL1 (0.61) | KCNH2OPRM1OPRL1DRD2 | |
| SCHEMBL6506056 | 0.79 | OPRL1 (0.61) | KCNH2OPRM1OPRL1DRD2 | |
| SCHEMBL6472755 | 0.76 | OPRM1 (0.54) | KCNH2OPRM1OPRL1CHRM4CHRM1 | |
| SCHEMBL6504782 | 0.74 | OPRL1 (0.67) | KCNH2OPRM1OPRL1 | |
| SCHEMBL6504786 | 0.74 | OPRL1 (0.67) | KCNH2OPRM1OPRL1 | |
| SCHEMBL6472721 | 0.73 | OPRL1 (0.63) | KCNH2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | KCNH2 378/4885OPRM1 8/4885OPRL1 1/4885 |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | OPRL1, ACHE, PNMT | KCNH2 942/4885OPRM1 112/4885OPRL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.